UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | V | W
Number of items: 176.

A

Anderson, FM; O'Hare, CC; Hartley, JA; Robins, DJ; (2000) Synthesis of new homochiral bispyrrolidines as potential DNA cross-linking antitumour agents. ANTI-CANCER DRUG DES , 15 (2) 119 - 126.

Arkenau, HT; Hegglin, I; Luthi, U; Gebbers, JO; (2000) Trichosporosis. Schweizerische Medizinische Wochenschrift , 130 (49) 1914-.

Arkenau, HT; Hegglin, I; Lüthi, U; (2000) [Trichosporosis]. Schweiz Med Wochenschr , 130 (49) 1914-.

Arkenau, HT; Luthi, U; (2000) Amyloidomas. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT , 130 (35) p. 1244.

Arkenau, HT; Luthi, U; (2000) Soap-bubble lesions. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT , 130 (51-52) p. 2017. Gold open access

Arkenau, HT; Luthi, U; Gebbers, JO; (2000) Amyloidomas. Schweizerische Medizinische Wochenschrift , 130 (35) 1244-.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Garman, EF; Gibson, AE; ... Yu, W; + view all (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J MED CHEM , 43 (15) 2797 - 2804.

Azzabi, AS; Calvert, AH; Verrill, M; Kelly, C; Lind, MJ; Newell, DR; Griffin, MJ; ... Boddy, AV; + view all (2000) Phase I and pharmacokinetic study of temozolomide and paclitaxel in the treatment of malignant melanoma. Clinical Cancer Research , 6 539-.

B

Baddeley, H; Brodrik, PM; Taylor, NJ; Abdelatti, MO; Jordan, LC; Vasudevan, AS; Phillips, H; ... Hoskin, PJ; + view all (2000) Gas exchange parameters in radiotherapy patients during breathing of 2%, 3.5% and 5% carbogen gas mixtures. British Journal of Radiology , 73 (874) pp. 1100-1104.

Barlow, HC; Bowman, KJ; Curtin, NJ; Calvert, AH; Golding, BT; Huang, B; Loughlin, PJ; ... Griffin, RJ; + view all (2000) Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha(1)-acid glycoprotein (AGP). BIOORG MED CHEM LETT , 10 (6) 585 - 589.

Baynes, KCR; Beeton, CA; Panayotou, G; Stein, R; Soos, M; Hansen, T; Simpson, H; ... Whitehead, JP; + view all (2000) Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. DIABETOLOGIA , 43 (3) pp. 321-331. 10.1007/s001250050050.

Bentley, J; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Gibson, AE; ... Newell, DR; + view all (2000) Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research , 6 328-.

Bentzen, SM; Hoskin, P; Roos, D; Nielsen, OS; (2000) Fractionated radiotherapy for metastatic bone pain: Evidence- based medicine or ...? International Journal of Radiation Oncology Biology Physics , 46 (3) pp. 681-682.

Bentzen, SM; Saunders, MI; Dische, S; Parmar, MK; (2000) Updated data for chart in NSCLC: Further analyses. RADIOTHERAPY AND ONCOLOGY , 55 (1) pp. 86-87. 10.1016/S0167-8140(00)00160-2.

Berardi, R; Strauss, S; Blake, D; Whelan, JS; (2000) Is it safe to substitute oral for intravenous mesna? A case control study. In:

Beverley, PCL; Maini, MK; (2000) Differences in the regulation of CD4 and CD8 T-cell clones during immune responses. In: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES. (pp. 401 - 406). ROYAL SOC LONDON

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; ... Begent, RH; + view all (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer , 85 (4) pp. 571-577.

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; ... Begent, RHJ; + view all (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv :: carboxypeptidase G2 fusion protein. INT J CANCER , 85 (4) 571 - 577.

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; ... Begent, RHJ; + view all (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. International Journal of Cancer , 85 (4) pp. 571-577. 10.1002/(SICI)1097-0215(20000215)85:4<571::AID-IJC20>3.0.CO;2-1.

Bhatia, J; Sharma, SK; Pedley, BR; Boxer, G; Robson, L; Begent, RHJ; Chester, K; (2000) In vitro & in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: (pp. p. 71). CHURCHILL LIVINGSTONE

Bhatia, J; Sharma, SK; Pedley, BR; Boxer, G; Robson, L; Begent, RHJ; Chester, K; (2000) In vitro and in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: (pp. p. 170).

Boddy, AV; Griffin, MJ; Wright, JG; Sludden, JA; Thomas, HD; Fishwick, K; Plummer, R; ... Calvert, AH; + view all (2000) Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer. British Journal of Cancer , 83 203-.

Boehm, MK; Corper, AL; Wan, T; Sohi, MK; Sutton, BJ; Thornton, JD; Keep, PA; ... Perkins, SJ; + view all (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J , 346 Pt pp. 519-528.

Boehm, MK; Corper, AL; Wan, T; Sohi, MK; Sutton, BJ; Thornton, JD; Keep, PA; ... Perkins, SJ; + view all (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. BIOCHEM J , 346 519 - 528.

Broadstock, M; Michie, S; Gray, J; Mackay, J; Marteau, TM; (2000) The psychological consequences of offering mutation searching in the family for those at risk of hereditary breast and ovarian cancer - A pilot study. PSYCHO-ONCOL , 9 (6) 537 - 548.

Brooks, N; McHugh, PJ; Lee, M; Hartley, JA; (2000) Alteration in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove. CHEM BIOL , 7 (9) 659 - 668.

Burcombe, RJ; Makris, A; Richman, PI; Daley, F; Noble, S; Wilson, GD; (2000) Persistence of c-erbB-2 overexpression after neoadjuvant chemotherapy for primary breast cancer. British Journal of Cancer , 83 36-.

Burcombe, RJ; Ostler, PJ; Ayoub, AW; Hoskin, PJ; (2000) The role of staging CT scans in the treatment of prostate cancer: A retrospective audit. Clinical Oncology , 12 (1) pp. 32-35.

C

COULONVAL, K; VANDEPUT, F; STEIN, RC; KOZMA, SC; LAMY, F; DUMONT, JE; (2000) Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochemical Journal , 348 (2) pp. 351-358. 10.1042/bj3480351.

Calabrese, CR; Curtin, NJ; Canan-Koch, SS; Batey, MA; Thomas, HD; Kyle, S; Wang, LZ; ... Newell, DR; + view all (2000) Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. Clinical Cancer Research , 6 150-.

Calabrese, CR; Curtin, NJ; Canan-Koch, SS; Batey, MA; Thomas, HD; Kyle, S; Wang, LZ; ... Newell, DR; + view all (2000) Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. CLIN CANCER RES , 6 4496S - 4496S.

Calvert, H; Sessa, C; Carmichael, J; Calvert, P; Zucchetti, M; Marsoni, S; Van den Bosch, S; ... Camboni, G; + view all (2000) An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex. ANN ONCOL , 11 132 - 132.

Calvert, P; Jayson, G; Atkinson, R; Ganesan, T; Cervantes-Ruiperez, A; Vasey, P; Adams, M; ... Cheverton, P; + view all (2000) Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane. Annals of Oncology , 11 372P-.

Calvert, PM; O'Neill, V; Azzabi, A; Hughes, A; Plummer, R; Twelves, C; Robinson, A; ... Calvert, AH; + view all (2000) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. Clinical Cancer Research , 6 575-.

Calvert, PM; O'Neill, V; Azzabi, A; Hughes, A; Plummer, R; Twelves, C; Robinson, A; ... Calvert, AH; + view all (2000) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. CLIN CANCER RES , 6 4581S - 4581S.

Cerone, MA; Marchetti, A; Bossi, G; Blandino, G; Sacchi, A; Soddu, S; (2000) p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death Differ , 7 (5) pp. 506-508. 10.1038/sj.cdd.4400676.

Chang, J; Powles, TJ; Allred, DC; Ashley, SE; Makris, A; Gregory, RK; Osborne, CK; (2000) Prediction of clinical outcome from primary tamosifen by expression of biologic markers in breast cancer patients. Clinical Cancer Research , 6 (2) pp. 616-621.

Chester, KA; Bhatia, J; Boxer, G; Cooke, SP; Flynn, AA; Huhalov, A; Mayer, A; ... Begent, RHJ; + view all (2000) Clinical applications of phage-derived sFvs and sFv fusion proteins. DISEASE MARKERS , 16 (1-2) 53 - 62.

Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DI; Cooke, SP; Flynn, AA; ... Begent, RH; + view all (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol , 46 Sup S8-12.

Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DIR; Cooke, SP; Flynn, AA; ... Begent, RHJ; + view all (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. (pp. S8 - S12). SPRINGER-VERLAG

Clingen, PH; Denholm, EE; De Silva, IU; Hockey, A; Hartley, JA; (2000) Response of human DNA repair defective cell lines to DNA interstrand agents. British Journal of Cancer , 83 138-.

Clingen, PH; Denholm, EE; De Silva, IU; Hockey, A; Hartley, JA; CRC Drug DNA Interaction Res Grp, ; (2000) Response of human DNA repair defective cell lines to DNA interstrand agents. BRIT J CANCER , 83 63 - 63.

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. British Journal of Cancer , 83 (Suppl) 14-.

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. BRIT J CANCER , 83 11 - 11.

Coulonval, K; Vandeput, F; Stein, RC; Kozma, SC; Lamy, F; Dumont, JE; (2000) Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J , 348 Pt pp. 351-358.

Cunningham, D; Mainwaring, PN; Gregory, W; Hoskin, P; Hancock, B; Smith, P; Hudson, GV; (2000) Mitoxantrone is superior to doxorubicin in a multi-agent weekly regimen for patients with high-grade lymphoma over the age of 60 years: Results of a BNLI randomised trial of PACEBO vs. British Journal of Cancer , 83 (Su 1-.

Curtin, NJ; Calvert, AH; Canan-Koch, S; Durkacz, BW; Griffin, RJ; Golding, BT; Hostomsky, Z; ... Yu, XH; + view all (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. Clinical Cancer Research , 6 205-.

Curtin, NJ; Calvert, AH; Canan-Koch, S; Durkacz, BW; Griffin, RJ; Golding, BT; Hostomsky, Z; ... Yu, XH; + view all (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. CLIN CANCER RES , 6 4507S - 4507S.

D

De Silva, IU; McHugh, PJ; Clingen, PH; Hartley, JA; (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. MOL CELL BIOL , 20 (21) 7980 - 7990.

Dearling, JLJ; Flynn, AA; Pagoulatos, C; Wilson, GD; Woodcock, M; Denholm, E; Hartley, J; ... Pedley, RB; + view all (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. British Journal of Cancer , 83 (Suppl) 173-.

Dearling, JLJ; Flynn, AA; Pagoulatos, C; Wilson, GD; Woodcock, M; Denholm, E; Hartley, J; ... Pedley, RB; + view all (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. In: BRIT J CANCER. (pp. 72 - 72). CHURCHILL LIVINGSTONE

Delaney, CA; Wang, LZ; Kyle, S; White, AW; Calvert, AH; Curtin, NJ; Durkacz, BW; ... Newell, DR; + view all (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. CLIN CANCER RES , 6 (7) 2860 - 2867.

Dey, A; McCloskey, EV; Taube, T; Cox, R; Panda, KC; Ashford, RU; Forster, M; ... Kanis, JA; + view all (2000) Metacarpal morphometry using a semi-automated technique in the assessment of osteoporosis and vertebral fracture risk. OSTEOPOROSIS INTERNATIONAL , 11 (11) pp. 953-958. 10.1007/s001980070034.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. British Journal of Cancer , 83 152-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. Clinical Cancer Research , 6 309-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. British Journal of Cancer , 83 152-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. Clinical Cancer Research , 6 309-.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. BRIT J CANCER , 83 66 - 66.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. CLIN CANCER RES , 6 4527S - 4527S.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazratis, A; Hartley, JA; Butler, J; (2000) The abnormal cytotoxicities of 2,5-diaziridinyl-1,4-benzoquinone-3-phenyl esters. ANTI-CANCER DRUG DES , 15 (5) 347 - 359.

Duchesne, GM; Bolger, JJ; Griffiths, GO; Roberts, JT; Graham, JD; Hoskin, PJ; Fossa, SD; ... Parmar, MKB; + view all (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: Results of Medical Research Council Trial BA09. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , 47 (2) pp. 379-388. 10.1016/S0360-3016(00)00430-2.

Dunlop, DJ; Connery, L; O, BM; Thatcher, N; Lee, SM; Hill, S; Thatcher, N; (2000) Phase II study of carboplatin and vinorelbine in small cell lung cancer. In: (Proceedings) 2000 ASCO Annual Meeting/36th Annual Meeting, New Orleans, LA.. (pp. 518a-). Proceedings of the American Society of Clinical Oncology

Dunlop, DJ; O'Brien, ME; Lee, SM; Hill, S; Thatcher, N; (2000) Multicentre phase II study of carboplatin (AUC 5) and vinorelbine in small cell lung cancer (SCLC). In: (pp. p. 42). CHURCHILL LIVINGSTONE

E

Eccles, DM; Evans, DG; Mackay, J; (2000) Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). Journal of Medical Genetics , 37 (3) pp. 203-209.

F

Francis, RJ; Sharma, SK; Sena, L; Springer, C; Green, AJ; Hope-Stone, LD; Martin, J; ... Begent, RHJ; + view all (2000) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. British Journal of Cancer , 83 (Suppl) 18-.

Francis, RJ; Sharma, SK; Sena, L; Springer, C; Green, AJ; Hope-Stone, LD; Martin, J; ... Begent, RHJ; + view all (2000) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. British Journal of Cancer , 83 43-.

Francis, RJ; Sharma, SK; Sena, L; Springer, C; Green, AJ; Hope-Stone, LD; Martin, J; ... Begent, RHJ; + view all (2000) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. BRIT J CANCER , 83 18 - 18.

Friedman, HS; Kerby, T; Calvert, H; (2000) Temozolomide and treatment of malignant glioma. CLIN CANCER RES , 6 (7) 2585 - 2597.

G

Gibson, V; Anderson, RJ; Hartley, JA; McAdam, SR; Cairns, D; (2000) Anthraquinone-oligodeoxynucleotide conjugates as inhibitors of gene transcription. J PHARM PHARMACOL , 52 (6) 599 - 602.

Gorodetsky, R; Lotan, C; Piggot, K; Pierce, L; Polyansky, I; Dische, S; Saunders, MI; ... Vexler, A; + view all (2000) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy (vol 45, pg 893, 1999). International Journal of Radiation Oncology Biology Physics , 47 (2) p. 545.

Griffin, RJ; Arris, CE; Bleasdale, C; Boyle, FT; Calvert, AH; Curtin, NJ; Dalby, C; ... Golding, BT; + view all (2000) Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine. J MED CHEM , 43 (22) 4071 - 4083. 10.1021/jm000961o.

Griffin, RJ; Arris, CE; Calvert, AH; Curtin, NJ; Jewsbury, P; Endicott, JA; Gibson, AE; ... Lawrie, A; + view all (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society , 219 296-MEDI.

Griffin, RJ; Arris, CE; Calvert, AH; Curtin, NJ; Jewsbury, P; Endicott, JA; Gibson, AE; ... Lawrie, A; + view all (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. ABSTR PAP AM CHEM S , 219 U55 - U55.

H

Hampel, C; Tolner, B; Webley, SD; Lam, E; Hartley, JA; Hochhauser, D; (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. British Journal of Cancer , 83 (Suppl) 65-.

Hampel, C; Tolner, B; Webley, SD; Lam, E; Hartley, JA; Hochhauser, D; (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. BRIT J CANCER , 83 23 - 23.

Hargreaves, RHJ; Hartley, JA; Butler, J; (2000) Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. FRONT BIOSCI , 5 E172 - E180.

Harland, PC; Harland, SJ; (2000) John Charles Harland - Obituaries. BMJ (Clinical Research Ed.) , 320 (7242) p. 1149.

Harland, SJ; (2000) Conundrum of the hereditary component of testicular cancer. LANCET , 356 (9240) 1455 - 1456.

Hartley, JA; Brooles, PJ; Mc Hugh, PJ; Clingen, PH; Gregson, SJ; Howard, PW; and Thurston, DE; (2000) SJG-136 (NSC-D694501)-A novel DNA sequence specific minor groove crosslinking agent with significant antitumor activity. PROC AM ASSOC CANCER RES , 41 2703-.

Hartley, JA; Hazrati, A; Hodgkinson, TJ; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; (2000) Synthesis, cytotoxicity and DNA cross-linking activity of symmetrical dimers based upon the epoxide domain of the azinomycins. CHEM COMMUN (23) 2325 - 2326.

Hartley, JA; Hazrati, A; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; Walker, LF; (2000) A Synthetic Azinomycin Analogue with Demonstrated DNA Cross-Linking Activity: Insights into the Mechanism of Action of this Class of Antitumor Agent The authors gratefully acknowledge the financial support provided by the CRC and the EPSRC. We are indebted to the EPSRC National Mass Spectrometry Centre for performing mass spectral measurements, and the EPSRC Chemical Database Service at Daresbury.1. Angew Chem Int Ed Engl , 39 (19) pp. 3467-3470.

Hartley, JA; Hazrati, A; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; Walker, LF; (2000) A synthetic azinomycin analogue with demonstrated DNA cross-linking activity: Insights into the mechanism of action of this class of antitumor agent. ANGEW CHEM INT EDIT , 39 (19) 3467 - +.

Hochhauser, D; (2000) Relevance of mitochondrial DNA in cancer. LANCET , 356 (9225) 181 - 182.

Hooshmand-Rad, R; Hajkova, L; Klint, P; Karlsson, R; Vanhaesebroeck, B; Claesson-Welsh, L; Heldin, CH; (2000) The PI 3-kinase isoforms p110 alpha and p110 beta have differential roles in PDGF- and insulin-mediated signaling. JOURNAL OF CELL SCIENCE , 113 (2) pp. 207-214.

Hooshmand-Rad, R; Hajkova, L; Klint, P; Karlsson, R; Vanhaesebroeck, B; Claesson-Welsh, L; Heldin, CH; (2000) The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in. Journal of Cell Science , 113 207 - 214.

Horwich, A; Oliver, RTD; Wilkinson, PM; Mead, GM; Harland, SJ; Cullen, MH; Roberts, JT; ... MRC Testicular Tumour Working Par, ; + view all (2000) A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. BRIT J CANCER , 83 (12) 1623 - 1629. 10.1054/bjoc.2000.1498.

Hoskin, PJ; (2000) Palliative radiotherapy for disseminated disease. In: Greco, C and Zelefsky, MJ, (eds.) Radiotherapy of prostate cancer. (pp. 463-477). Harwood Academic Publishers: Amsterdam.

Hoskin, PJ; (2000) Bone metastases - radiotherapy. In: Rubens, RD and Mundy, GR and Martin, D, (eds.) Cancer and the skeleton. (pp. 159-170). : London.

Hoskin, PJ; Phillips, H; Jackson, S; Wims, P; Verma, N; Saunders, MI; (2000) Carbogen and nicotinamide with radical radiotherapy for bladder cancer: Updated Phase II results and launch of the BCON Phase III randomised trial. British Journal of Cancer , 83 84-.

Hoskin, PJ; Stratford, MRL; Folkes, LK; Regan, J; Yarnold, JR; (2000) Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. The Lancet , 355 (9213) pp. 1428-1429.

Hoskin, PJ; Vidler, K; (2000) Vaginal vault brachytherapy: the effect of varying bladder volumes on normal tissue dosimetry. British Journal of Radiology , 73 (872) pp. 864-866.

Hughes, AN; Griffin, MJ; Newell, DR; Calvert, AH; Johnston, A; Kerr, B; Lee, C; ... Boddy, AV; + view all (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel. BRIT J CANCER , 82 (9) 1519 - 1527.

Hughes, AN; Griffin, MJ; Newell, DR; Calvert, AH; Johnston, A; Kerr, B; Lee, C; ... Boddy, AV; + view all (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel. BRIT J CANCER , 82 (9) 1519 - 1527.

J

Jankowska, PJ; Babb, P; Quinn, M; Whelan, JS; (2000) A population based study of the incidence and mortality for osteosarcoma in England and Wales. In:

Joiner, M; Short, S; Mayes, C; Lambin, P; Marples, B; Shah, N; Saunders, MI; (2000) Low dose hypersensitivity and induced radioresistance: Possibilities for therapy and implications for radioprotection. International Journal of Radiation Oncology Biology Physics , 46 (3) p. 692.

K

Kinashi, T; Katagiri, K; Watanabe, S; Vanhaesebroeck, B; Downward, J; Takatsu, K; (2000) Distinct mechanisms of alpha(5)beta(1) integrin activation by Ha-Ras and R-Ras. JOURNAL OF BIOLOGICAL CHEMISTRY , 275 (29) pp. 22590-22596. 10.1074/jbc.M000633200. Gold open access

L

Leonard, P; Ledermann, J; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5-fluorouracil (5-FU) and folinic acid for first and second line treatment of advanced colorectal cancer. ANN ONCOL , 11 44 - 45.

Leonard, P; Ledermann, JA; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5-FU and folinic acid (modified de Gramont) for first-line treatment of advanced or metastatic colorectal cancer. British Journal of Cancer , 83 44-.

Leonard, P; Ledermann, JA; James, R; Hochhauser, D; Seymour, M; (2000) Phase II study of irinotecan and high dose infusional 5-FU and folinic acid (modified de Gramont) for first-line treatment of advanced or metastatic colorectal cancer. BRIT J CANCER , 83 19 - 19.

Lo, SK; Tolner, B; Rogers, G; Schapira, AHV; Hartley, JA; Hochhauser, D; (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. British Journal of Cancer , 83 56-.

Lo, SK; Tolner, B; Rogers, G; Schapira, AHV; Hartley, JA; Hochhauser, D; (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. BRIT J CANCER , 83 22 - 22.

M

Mackay, J; (2000) Genetic testing in breast cancer patients: options for gene carriers and high risk women. In: Dixon, JM, (ed.) Breast Cancer: Diagnosis and Management. (pp. 107-112).

Maini, MK; Gudgeon, N; Wedderburn, LR; Rickinson, AB; Beverley, PCL; (2000) Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J IMMUNOL , 165 (10) 5729 - 5737.

Mayer, A; Tsiompanou, E; O'Malley, D; Boxer, GM; Bhatia, J; Flynn, AA; Chester, KA; ... Begent, RHJ; + view all (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. CLIN CANCER RES , 6 (5) 1711 - 1719.

McHugh, PJ; Hartley, JA; (2000) Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair. British Journal of Cancer , 83 139-.

McHugh, PJ; Hartley, JA; CRC Drug DNA Interactions Res Grp, ; (2000) Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair. BRIT J CANCER , 83 63 - 63.

McHugh, PJ; Sones, WR; Hartley, JA; (2000) Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. MOL CELL BIOL , 20 (10) 3425 - 3433.

McNeish, IA; Kanfer, EJ; Haynes, R; Agarwal, R; Harland, SJ; Newlands, ES; Seckl, MJ; (2000) Paclitaxel-containing high dose chemotherapy for relapsed or refractory germ cell tumours. British Journal of Cancer , 83 86-.

Meyer, T; Rustin, GJ; (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer , 82 (9) pp. 1535-1538. 10.1054/bjoc.2000.1174.

Middleton, MR; Lee, SM; Aranc, ; A, ; Wood, M; Thatcher, N; Margison, GP; (2000) 06-methyguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. International Journal of Cancer , 88 (3) pp. 469-473.

Middleton, MR; Lorigan, P; Owens, J; Ashcroft, L; Lee, SM; Harper, P; Thatcher, N; (2000) A randomised phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British Journal of Cancer , 82 (6) pp. 1158-1162.

Middleton, MR; Ranson, M; Lee, SM; Bridgewater, J; McElhinney, RS; McMurry, TBH; Thatcher, N; ... Margison, GP; + view all (2000) Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. CLIN CANCER RES , 6 4574S - 4574S.

Middleton, MR; Ranson, M; Lee, SM; Bridgewater, J; McElhinney, RS; McMurry, TBH; Thatcher, N; ... Margison, GP; + view all (2000) Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. In: (Proceedings) 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam.. (pp. 4574S-). Clinical Cancer Research

Millar, J; Thirlwell, C; (2000) Effects of adenosine on NMDA-responsive cells in the rat dorsal horn. JOURNAL OF PHYSIOLOGY-LONDON , 523 199P-199P.

Mitjans, F; Meyer, T; Fittschen, C; Goodman, S; Jonczyk, A; Marshall, JF; Reyes, G; (2000) In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer , 87 (5) pp. 716-723.

N

Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; ... Begent, RH; + view all (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res , 6 (3) pp. 765-772.

Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; ... Begent, RHJ; + view all (2000) Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. CLIN CANCER RES , 6 (3) 765 - 772.

O

Osborne, M; Glynne-Jones, A; Makris, A; (2000) Chemoradiation followed by immediate boost in squamous cell carcinoma of the anus. British Journal of Cancer , 83 71-.

P

Patterson, LH; Paniwynk, Z; Pohrs, K; Teesdale-Spittle, PH; Hartley, JA; Plumb, J; (2000) A novel alkylating anthraquinone that is effective against resistant ovarian cancer cells. Proceedings of the American Association for Cancer Research , 41 2701-.

Pavlidis, N; Aamdal, S; Awada, A; Calvert, H; Fumoleau, P; Sorio, R; Punt, C; ... Hanauske, AR; + view all (2000) Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). CANCER CHEMOTH PHARM , 46 (2) 167 - 171.

Pedley, RB; Sharma, SK; Boxer, G; Flynn, AA; Boden, R; Watson, R; Dearling, J; ... Begent, RHJ; + view all (2000) Tumour eradication by combined antibody-directed and antivascular therapy. BRIT J CANCER , 83 13 - 13.

Pettet, E; Phillips, H; Jackson, S; Saunders, MI; (2000) The time span between symptom onset and the start of radiotherapy in the treatment of head and neck tumours - A retrospective review. British Journal of Cancer , 83 78-.

Pharoah, P; Mackay, J; (2000) Medical genetics and breast cancer: current thinking on the utility of genetic screening in the determination of clinical risk. In: Mansel, R and Smith, IE and Kunkler, I and Miles, A, (eds.) The Effective Management of Breast Cancer. (pp. 13-28). Aesculapius: London.

Pigott, KH; Dische, S; Vojnovic, B; Saunders, MI; (2000) Sweat gland function as a measure of radiation change. Radiotherapy And Oncology , 54 (1) pp. 79-85.

Porrello, A; Cerone, MA; Coen, S; Gurtner, A; Fontemaggi, G; Cimino, L; Piaggio, G; ... Soddu, S; + view all (2000) p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol , 151 (6) pp. 1295-1304.

Pritchard, JK; Lewis, I; Whelan, JS; Hale, J; Pagonis, C; Durrant, LG; (2000) Immune response to the anti-idiotype cancer vaccine, 105AD7, following chemotherapy in osteosarcoma patients. In:

R

Raymond, EE; Fumoleau, P; Roche, H; Schellens, JHM; Dittrich, C; Punt, CJA; Droz, JP; ... Ravic, M; + view all (2000) Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clinical Cancer Research , 6 315-.

Rogers, S; Whelan, JS; (2000) Cerebral metastases from malignant fibrous histiocytoma of bone. Sarcoma , 4 pp. 125-128. Gold open access

Roos, DE; Davis, SR; O'Brien, PC; Hoskin, PJ; (2000) Eligibility audits form the randomised neuropathic bone trial (TROG 96.05). Australasian Radiology , 44 pp. 303-307.

Roos, DE; O'Brien, PC; Smith, JG; Spry, NA; Hoskin, PJ; Burmeister, BH; Turner, SL; (2000) A role for radiotherapy in neuropathic bone pain: Preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96.05). International Journal of Radiation Oncology Biology Physics , 46 (4) pp. 975-981.

Rudd, RM; Gower, NH; James, LE; Gregory, W; Eisen, TQ; Lee, SM; et, A; (2000) A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). In: (Proceedings) 9th World Conference on Lung Cancer, Tokyo, Japan.. (pp. 21-). Lung Cancer

S

Saifuddin, A; Whelan, J; Pringle, JAS; Cannon, SR; (2000) Malignant round cell tumours of bone: atypical clinical and imaging features. SKELETAL RADIOL , 29 (11) 646 - 651.

Saunders, MI; (2000) The implications and opportunities of the CHART trial in the treatment of non-small cell lung cancer. British Journal of Cancer , 83 S5-.

Shah, EF; Woodside, J; Chatterjee, R; Stein, R; Saunders, C; (2000) The role of Zoladex in the prevention of ovarian damage during chemotherapy for primary breast cancer. BRIT J CANCER , 83 40 - 40.

Shah, N; Groom, N; Jackson, S; Sibtain, A; Hoskin, P; (2000) A pilot study to assess the feasibility of prior scalp cooling with palliative whole brain radiotherapy. British Journal of Radiology , 73 (869) pp. 514-516.

Shah, N; Hoskin, P; McMillan, A; Gibson, P; Lowe, J; Wong, WL; (2000) The impact of FDG positron emission tomography imaging on the management of lymphomas. British Journal of Radiology , 73 (869) pp. 482-487.

Shah, N; Hoskin, P; Sibtain, A; Baddeley, H; Taylor, J; Saunders, M; (2000) Blood oxygen level dependent (BOLD) MRI imaging: A non invasive assessment of hypoxia and perfusion in solid tumours. British Journal of Cancer , 83 15-.

Shah, N; Saunders, M; Dische, S; (2000) A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. British Journal of Cancer , 83 77-.

Shah, N; Sibtain, A; Saunders, MI; Townsend, E; Wong, WL; (2000) High FDG uptake in a schwanomma: A PET study. Journal Of Computer Assisted Tomography , 24 (1) pp. 55-56.

Shamash, J; Lee, SM; Radford, JA; Rohatiner, AZS; Chang, J; Morgenstern, OR; Scarffe, JH; ... Lister, TA; + view all (2000) Patterns of relapse and subsequent management following high dose chemotherapy with autologous haemopoietic support in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology , 11 (6) pp. 715-719.

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. In: (pp. p. 172).

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. BRIT J CANCER , 83 71 - 71.

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KAAB; R, HJ; (2000) In vivo characteristics of a glycosylated fusion protein for prodrug activation. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 710-).

Short, S; (2000) UNSPECIFIED In: (Proceedings) Radiobiology 2000, Trivandrum, India.

Short, S; C, B; M, ; (2000) The treatment of malignant cerebral tumours. Hospital Medicine , 61 (11) pp. 772-777.

Short, SC; Traish, D; Dowe, A; Hines, F; Brada, M; (2000) UNSPECIFIED In: (Proceedings) 4th Congress of the European Association for Neuro-Oncology.

Sibtain, A; Bradshaw, A; Shah, N; Hoskin, PJ; (2000) Late complications of mantle radiotherapy for Hodgkin's lymphoma. British Journal of Cancer , 83 223-.

Sibtain, A; Hill, SA; Goodchild, KA; Shah, N; Saunders, MI; Hoskin, PJ; (2000) Modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. British Journal of Cancer , 83 15-.

Sibtain, A; Shah, N; Saunders, MI; Hoskin, PJ; (2000) Is there a relationship between pre-treatment haemoglobin and outcome in non-small cell lung cancer treated with radiotherapy? British Journal of Cancer , 83 58-.

Smith, PG; Thomas, HD; Barlow, HC; Griffin, RJ; Golding, BT; Calvert, AH; Newell, DR; (2000) In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121. Clinical Cancer Research , 6 445-.

Spanswick, VJ; Craddock, C; Sekhar, M; Hartley, JA; (2000) Repair of DNA interstrand crosslinks as a mechanism clinical resistance to melphalan in multiple myeloma. British Journal of Cancer , 83 35-.

Spanswick, VJ; Craddock, C; Sekhar, M; Hartley, JA; (2000) Repair of DNA interstrand crosslinks as a mechanism clinical resistance to melphalan in multiple myeloma. BRIT J CANCER , 83 16 - 16.

Spanswick, VJ; Craddock, C; Sekhar, M; Hartley, JA; (2000) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. British Journal of Cancer , 83 (Suppl) 35-.

Spencer, DIR; Purdy, D; Minton, N; Whitelegg, NR; Rees, AR; Begent, RHJ; Chester, KA; (2000) Mutating ADEPT enzyme CPG2 to reduce its immunogenicity. British Journal of Cancer , 83 (Suppl) 171-.

Spencer, DIR; Purdy, D; Minton, N; Whitelegg, NR; Rees, AR; Begent, RHJ; Chester, KA; (2000) Mutating ADEPT enzyme CPG2 to reduce its immunogenicity. BRIT J CANCER , 83 71 - 71.

Stein, RC; Waterfield, MD; (2000) PI3-kinase inhibition: a target for drug development? MOLECULAR MEDICINE TODAY , 6 (9) pp. 347-357. 10.1016/S1357-4310(00)01770-6.

Strauss, S; McTiernan, A; Driver, D; Hall-Craggs, M; Sandison, A; Cassoni, A; Kilby, A; ... Whelan, JS; + view all (2000) A single centre experience of an intensive induction therapy (VIDE) including stem cell collection for Ewing’s family of tumours (EFT). In:

Strauss, S; McTiernan, A; Whelan, JS; (2000) Spontaneous regression of pulmonary metastases in three patients with bone and soft tissue sarcomas. In:

T

Thomas, HD; Lind, MJ; Ford, J; Bleehen, N; Calvert, AH; Boddy, AV; (2000) Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. CANCER CHEMOTH PHARM , 45 (4) 284 - 290.

Tolner, B; Hartley, JA; Hochhauser, D; (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. British Journal of Cancer , 83 165-.

Tolner, B; Hartley, JA; Hochhauser, D; (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. British Journal of Cancer , 83 165-.

Tolner, B; Hartley, JA; Hochhauser, D; (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. BRIT J CANCER , 83 70 - 70.

Tsiompanou, E; Boxer, GM; Levine, T; Begent, RHJ; (2000) Immunohistochemical expression of vascular endothelial growth factor (VEGF) and vessel counting as prognostic indicators in node-negative colorectal cancer. BRIT J CANCER , 83 29 - 29.

ten Dam, GB; Zilch, CF; Wallace, D; Wieringa, B; Beverley, PCL; Poels, LG; Screaton, GR; (2000) Regulation of alternative splicing of CD45 by antagonistic effects of SR protein splicing factors. J IMMUNOL , 164 (10) 5287 - 5295.

V

Vanhaesebroeck, B; Alessi, DR; (2000) The PI3K-PDK1 connection: more than just a road to PKB. BIOCHEMICAL JOURNAL , 346 pp. 561-576. 10.1042/0264-6021:3460561.

Verweij, J; Lee, SM; Ruka, W; Buesa, J; Coleman, R; van, HR; Seynaeve, C; ... Judson, IR; + view all (2000) Randomised phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. Journal of Clinical Oncology , 18 (10) pp. 2081-2086.

W

Waibel, R; Stichelberger, R; Alberto, R; Schubiger, PA; Chester, KA; Begent, RHJ; (2000) Site-directed labelling of single chain antibodies with 99(m)technetium and (188)rhenium. In: (pp. p. 15).

Westbury, C; Hines, F; Hawkes, E; Ashley, S; Brada, M; (2000) Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial. Radiother Oncol , 54 (2) pp. 109-116.

Westbury, C; Vini, L; Fisher, C; Harmer, C; (2000) Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid , 10 (2) pp. 171-176. 10.1089/thy.2000.10.171.

Whelan, JS; (2000) Multidisciplinary care in a dedicated teenage cancer unit. In:

Whelan, JS; McTiernan, A; (2000) A Phase II study of docetaxel for the treatment of recurrent osteosarcoma and Ewing’s tumours. In:

Whelan, JS; Weeden, S; Uscinska, B; McTiernan, A; (2000) Prolonged follow up of extremity osteosarcoma. Results from the European Osteosarcoma Intergroup. In:

Whelan, JS; Weeden, S; Uscinska, B; McTiernan, A; European Osteosarcoma Intergrp, ; (2000) Long-term survival in localised extremity osteosarcoma: Mature follow-up from two randomised trials of the European Osteosarcoma Intergroup. In: BRIT J CANCER. (pp. 18 - 18). CHURCHILL LIVINGSTONE

Whelan, JS; Weeden, S; Uscinska, B; McTiernan, AFTEOI; (2000) Localised extremity osteosarcoma: Mature survival data from two European Osteosarcoma Intergroup randomised clinical trials. In:

White, AW; Almassy, R; Calvert, AH; Curtin, NJ; Griffin, RJ; Hostomsky, Z; Maegley, K; ... Golding, BT; + view all (2000) Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J MED CHEM , 43 (22) 4084 - 4097. 10.1021/jm000950v.

Wong, NK; Kanu, N; Thandrayen, N; Rademaker, GJ; Baldwin, CI; Renouf, DV; Hounsell, EF; (2000) Microassay analyses of protein glycosylation. Mol Biotechnol , 14 (2) pp. 147-155. 10.1385/MB:14:2:147.

This list was generated on Sun Dec 17 02:20:38 2017 GMT.